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BACKGROUND: Neuroblastoma is an embryonic tumour of the sympathetic nervous system, metastatic in half of the patients at
diagnosis, with a high preponderance of osteomedullary disease, making accurate evaluation of metastatic sites and response to
therapy challenging. Metaiodobenzylguanidine (mIBG), taken into cells via the norepinephrine transporter, provides a sensitive and
specific method of assessing tumour in both soft tissue and bone sites. The goal of this report was to develop consensus guidelines for
the use of mIBG scans in staging, response assessment and surveillance in neuroblastoma.
METHODS: The International Neuroblastoma Risk Group (INRG) Task Force, including a multidisciplinary group in paediatric oncology
of North and South America, Europe, Oceania and Asia, formed a subcommittee on metastatic disease evaluation, including expert
nuclear medicine physicians and oncologists, who developed these guidelines based on their experience and the medical literature,
with approval by the larger INRG Task Force.
RESULTS: Guidelines for patient preparation, radiotracer administration, techniques of scanning including timing, energy, specific views,
and use of single photon emission computed tomography are included. Optimal timing of scans in relation to therapy and for
surveillance is reviewed. Validated semi-quantitative scoring methods in current use are reviewed, with recommendations for use in
prognosis and response evaluation.
CONCLUSIONS: Metaiodobenzylguanidine scans are the most sensitive and specific method of staging and response evaluation in
neuroblastoma, particularly when used with a semi-quantitative scoring method. Use of the optimal techniques for mIBG in staging
and response, including a semi-quantitative score, is essential for evaluation of the efficacy of new therapy.
British Journal of Cancer (2010) 102, 1319–1326. doi:10.1038/sj.bjc.6605621 www.bjcancer.com
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Neuroblastoma, the most common extra-cranial solid tumour in
children, originates as a primary tumour of the sympathetic
nervous system but metastasises commonly to bone and bone
marrow, resulting in a poor prognosis. The frequency and the
diffuse nature of the bone and bone marrow metastatic sites
mandate a reliable, quantitative and consistent method of
evaluation to assess response to therapy.
Metaiodobenzylguanidine (mIBG) is a guanethidine derivative
and an analogue of norepinephrine and is therefore specifically
taken up and stored in tumours derived from tissues of
sympathetic nervous system origin, which express the norepi-
nephrine transporter (Mairs et al, 1994; Boyd et al, 1999;
McCluskey et al, 2005; Moroz et al, 2007). Owing to the high
specificity and sensitivity in neuroblastoma, 123I-mIBG imaging
has superseded the use of 99mTc -technetium bone scans for the
detection of skeletal metastases in the majority of children with
neuroblastoma, which take up the tracer in 490% of cases, and
has been recommended by the last international consensus
conference as a standard element of staging and response
evaluation (Hadley and Rabe, 1986; Lumbroso et al, 1988; Brodeur
et al, 1993; Hero et al, 2001).
There is strong rationale for the use of 123I-mIBG scintigraphy
in assessing response to therapy, as it provides a very sensitive
marker of unsuspected skeletal and nodal disease and functional
evidence of residual active tumour. With the widespread use of
therapeutic 131I-mIBG as a targeted radiopharmaceutical treatment
of neuroblastoma both in newly diagnosed and relapsed patients,
diagnostic mIBG scans will determine the eligibility for this
modality (Garaventa et al, 1999; Gaze et al, 2005; Matthay et al,
2006, 2007; de Kraker et al, 2008; DuBois and Matthay, 2008).
Previous studies have indicated that a positive mIBG scan after
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induction chemotherapy or just before myeloablative therapy may
be a prognostic marker for a high likelihood of relapse (Ladenstein
et al, 1998; Perel et al, 1999; Schmidt et al, 2008). Several
publications have reported the use of semi-quantitative scoring
systems to increase the precision and inter-observer reliability of
this test, with success in correlating the results of mIBG scans with
early response and event-free survival in some, but not all, reports
(Ady et al, 1995; Suc et al, 1996; Frappaz et al, 2000; Hero et al,
2001; Matthay et al, 2003b; Katzenstein et al, 2004). As treatment of
stage 4 neuroblastoma continues to be a challenge, with a high rate
of relapse in bone and bone marrow, it is essential to have a
quantitative and reliable measure of response in bone metastases
to test the activity of new therapies for this disease (Messina et al,
2006). The previous international consensus conference on
neuroblastoma staging and response criteria recommended mIBG
scans as part of the evaluation, but did not clearly define how to
interpret a partial response by mIBG scan (Brodeur et al, 1993).
To facilitate comparisons of disease extent and response, one of
the goals of the International Neuroblastoma Risk Group (INRG)
Task Force, first convened in 2004, was to reach international
consensus on the standard procedures for performing, interpreting
and scoring mIBG scans. To facilitate comparison of clinical trials
performed throughout the world, the William Guy Forbeck
Research Foundation sponsored an international conference in
September 2005 by inviting experts from the major cooperative
groups in North America, Europe and Japan, as well as
investigators from Australia and China. They were organised into
four committees. The statistical, surgical and biological committee
developed the INRG risk classification based on the statistical
analysis of relevant prognostic factors, the INRG Staging System
based on image-defined surgical risk factors, and procedures for
the analysis of relevant biological markers (Ambros et al, 2009;
Cohn et al, 2009; Monclair et al, 2009). The fourth committee was
established to develop standard guidelines for detection and
quantification of metastatic disease, including minimal disease in
bone marrow and blood. One subcommittee reached a consensus
on the techniques for semi-quantitative evaluation of bone marrow
disease by immunocytology and RT–PCR (Beiske et al, 2009); the
current subcommittee, composed of oncologists and nuclear
medicine physicians, developed the guidelines for evaluation and
standardised comparison of metastatic disease detected by
123I-mIBG scans, reported in this paper.
STANDARDISED PROCEDURES FOR MIBG
SCINTIGRAPHY
For details on the mIBG scan procedure, refer Shulkin and Shapiro
(1998), Olivier et al (2003) and Bombardieri et al (2003).
Thyroid blockade
Thyroid blockade is important to protect the organ from
unnecessary irradiation from radioactive iodide that may dis-
sociate from the mIBG. Thyroid blockade for 123I-mIBG scans
can be achieved using aqueous iodine solution, oral potassium
iodide (100mg adult or 2mg kg–1 children) or potassium iodate
commencing 2–24 h before radiopharmaceutical injection and
continuing for 1 day after, in accordance with local protocols or
the European guidelines (Olivier et al, 2003). If a patient is allergic
to iodine, oral potassium perchlorate may be substituted, given
three times daily starting 2–24 h before and continuing for 2 days
after, at a dose of 8mg kg–1 (400mg for adult).
Drug interactions
Many classes of medicine have the potential to interfere with mIBG
uptake and storage, so care should be taken before prescribing
medications around the time of mIBG scan (Giammarile et al,
2008). The most commonly encountered agents that interfere with
mIBG uptake and retention in children are alpha- and beta-
adrenergic antagonists, such as pseudoephedrine and labetolol
(Babich et al, 1997). Pseudoephedrine is a decongestant found in
many over-the-counter cough and cold preparations, and labetolol
is a beta-adrenergic antagonist for blood pressure control. The
latter is usually quite effective for treatment of neuroblastoma-
associated hypertension, but must be discontinued for several days
before mIBG administration. Phenothiazines may interfere with
mIBG uptake and should be avoided as sedatives before imaging.
Phenylpropanolamine is another cough and cold preparation that
also interferes with mIBG uptake and retention, but is no longer
widely available. Serotonin re-uptake inhibitors have been listed as
possibly inhibitory, but early laboratory data did not support their
ability to inhibit mIBG uptake (Guilloteau et al, 1988), although
some more recent reports show that venlafaxine and duloxetine
can block norepinephrine reuptake (Lindauer et al, 2008; Tuccori
et al, 2009). Cocaine, tricyclic antidepressants and reserpine are
very rarely encountered inhibitors of mIBG uptake in children, but
a tumour without mIBG uptake should always raise the question of
possible interfering substances; however, it is rare that uptake is
completely blocked.
Radiopharmaceutical
Metaiodobenzylguanidine labelled with 123I is the radiopharma-
ceutical of choice in children for high-quality functional imaging
of neuroblastoma. The gamma emission energy of 159 keV from
123I is more suitable for imaging than the 364 keV from 131I, and
the differences in terms of radiation burden permit injection of
10- to 20-fold higher activities with 123I compared with 131I. The
radiopharmaceutical is injected slowly over 0.5–1min, usually via
a peripheral vein, and flushed with saline. Rapid injection is
contraindicated as it may cause adverse effects (vomiting,
tachycardia, pallor abdominal pain). If possible, injection
of central venous catheters should be avoided for technical reasons
such as visualisation of the catheter. If a central venous
catheter is used, it should be flushed well after injection and the
site noted.
The sensitivity of detection with mIBG increases with increased
activity injected, as shown for both 131I-mIBG and 123I-mIBG pre-
therapy diagnostic scans compared with immediate post-treatment
131I-mIBG scans (Parisi et al, 1992; Hickeson et al, 2004).
Furthermore, in the high-risk neuroblastoma patient group the
radiation hazard is far less than the risk resulting from false-
negative or false-positive scanning results (Stabin and Gelfand,
1998). Since longer scanning times may result in motion artefact, a
sufficient count rate is necessary to obtain scintigrams of good
quality within a short scanning time. Although rigorous paediatric
dose-finding studies have not been performed, the European
Association of Nuclear Medicine recommends that the adminis-
tered activity should be calculated on a reference adult dose of
370MBq scaled down for body weight (or body surface area) using
the factors adjusted for weight in Table 1 of the Lassmann
publication, with a minimum activity of 80MBq (Jacobs et al, 2005;
Lassmann et al, 2007). The need for high-quality images in patients
with this often lethal malignancy and the danger of under-staging
patients because of inadequate counts from the study, outweigh
the theoretical risks from a slightly higher dose of the radiotracer
(Bombardieri et al, 2003). Good hydration before and after the
injection will lower the radiation burden and reduce bladder
activity, which could interfere with evaluation of the pelvis.
Radiation dose per unit activity administered for 123I-labelled
mIBG is shown in Table 1, although in cases of pathological uptake
it is more difficult to estimate the organ and whole body dose
(Stabin and Gelfand, 1998).
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Image acquisition
Sedation is usually not required for a technically satisfactory
examination, except for children between 1 and 3 years, and others
who are unable to cooperate. Using 123I-mIBG, imaging is acquired
between 20 and 24 h after the injection. Selected delayed images at
48 h may be useful in cases with equivocal findings, such
as abdominal uptake that cannot be differentiated from the bowel
(Rufini et al, 1996). Some institutions have chosen to obtain very
early images, for example, at 4 h after injection, in addition to the
routine 24-h images. Tumour uptake may become more distinct at
later times compared with physiological uptake. In most institu-
tions, early images are not obtained and not thought helpful.
As the principal energy of 123I is 159 keV, we recommend low-
energy, high-resolution collimators, although scatter from addi-
tional low-abundance high-energy photon emission can degrade
image quality. Therefore, it is possible to use a medium energy
collimator and higher acquisition times, to minimise scatter with a
similar sensitivity. The pixel size is approximately 2mm, which
requires a 256 256 matrix (preferred) or 128 128 with zoom.
Views
The highest-quality images are obtained by having the child as
close as possible to the camera face. Spot images of the entire
body, including the skull (anterior, posterior and lateral views),
chest (anterior and posterior views), abdomen (anterior and
posterior views), pelvis (with empty bladder, anterior and poster-
ior views), upper and lower limbs (anterior and posterior
views) are the traditional method, but can be time consuming.
However, whole body scan imaging with additional spot images
including lateral views of the skull is often used and is equally
acceptable. Spot views, if obtained, should be acquired in
both the anterior and posterior planes from the top of the head
through the pelvis. Anterior images of the lower extremities
only are acceptable in institutions in which a dual-headed
gamma camera is not available. Lateral images are sometimes
valuable to discriminate between areas of overlapping uptake,
for example, in the abdomen or pelvis, especially if the bladder is
not empty.
Minimum 10min per view for spot images (or 250 Kcounts for
the skull and the trunk and 100 Kcounts for the lower limbs) is a
suitable compromise between best image quality and limitation of
scanning time. A fixed time of imaging is preferable to allow direct
comparison of intensity between sets of images without image
manipulation. For whole body scanning, a scan speed of 5 cmmin–1
is appropriate when available. A whole body scan will require
approximately 15min in a 1-year-old, 17min in a 2-year-old,
22min in a 5-year-old, 28min in a 10-year-old and 34min in a
15-year-old.
SPECT imaging
The feasibility of single photon emission computed tomography
(SPECT) will depend on the child’s cooperation and on the
equipment available (multiple head camera). However, in cases in
which uncertainty exists as to the exact site of mIBG activity,
SPECT should be performed, even if sedation is required. The
abdomen is the area in which this is most likely to occur, and less
frequently, the chest. Lesions in or close to the liver, as well as
close to the bladder or any other area of intense physiological
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Figure 1 (A)123I-mIBG scoring method 1: method 1 divides the skeleton into nine segments to view osteomedullary involvement, and adds a tenth sector
that counts any soft tissue involvement to the score. The extension score for method 1 is graded as: 0, no sites per segment; 1, one site per segment; 2, more
than one site per segment; and 3, diffuse involvement (450% of the segment). (B) 123I-mIBG scoring Frappaz-method 2: method 2 divides the skeleton into
seven segments. The intensity score for method 2 is graded as: 0, no uptake; 1, doubtful uptake; 2, obvious but mild uptake; 3, strong uptake, with a
maximum score of 21. Soft tissue involvement is noted separately from the score. (C) 123I-mIBG scoring SIOPEN-method 3: method 3 divides the skeleton
into 12 anatomic segments. The extension score for method 3 is graded as: 0, no sites per segment, 1, one discrete site per segment; 2, two discrete lesions;
3, three discrete lesions; 4,43 discrete foci or a single diffuse lesions involvingo50% of a bone; 5, diffuse involvement of450–95% whole bone; 6, diffuse
involvement of the entire bone.
Table 1 Radiation absorbed dose with 123I-mIBG scan (ICRP, 1998)
Age
MBq
administered lSvMBq1
Effective dose per
administration (mSv)
Adult 370 13 4.81
15 340 17 5.79
10 240 26 6.25
5 170 37 6.30
1 100 68 6.79
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uptake are particularly good indications to add SPECT, because
some tumour sites can only be observed on SPECT (Gelfand et al,
1994; Rufini et al, 1995, 1996). Single photon emission computed
tomography allows better comparison with anatomical imaging
data, in particular when image fusion with CT or MR image is
possible, or a combined SPECT–CT scanner is available (Tang
et al, 2001; Rozovsky et al, 2008).
Single photon emission computed tomographyacquisition
should be performed on a 128 128 matrix, 31 steps, with
30–35 s per step. Iterative reconstruction with a low-pass post-
filter is preferred to filter back-projection reconstruction. If the
acquisition time is too long and the child cannot or will not
cooperate, SPECT using 61 instead of 31 steps or using a 64 64
matrix with shorter times per frame can be used.
MIBG FOR STAGING AT DIAGNOSIS
123I-mIBG scans are essential for initial staging of neuroblastoma,
as they have a specificity of 85–96% (Leung et al, 1997). A recent
study using blinded readers and concomitant pathology, CT scan
and clinical information showed that 123I-mIBG scintigraphy had a
sensitivity of 88% and a specificity of 83% (Vik et al, 2009).
Occasionally, false-positive readings may occur because of uptake
in mature ganglioneuroma or other neuroendocrine tumours, or
because of physiological uptake that may be mistaken for tumour
in the adrenal gland, salivary gland, nasopharynx, brown fat or
excretion through renal pelvis and bladder (Pfluger et al, 2003).
False-negative scans may be observed in approximately 10% of
neuroblastomas that do not concentrate mIBG, owing to low
expression of the norepinephrine transporter (Carlin et al, 2003),
or owing to blood–brain barrier or large areas of scar or necrosis
(Matthay et al, 2003a). In addition, very small amounts of bone
marrow tumour will often not be detected, and therefore mIBG
scan must be supplemented with bilateral bone marrow biopsy
(Hero et al, 2001; Kushner et al, 2003). Metaiodobenzylguanidine
score at diagnosis may be prognostic, as higher scores, indicating a
high body burden of tumour, have been associated with a poorer
outcome in some studies. For example, Suc et al (1996) have
shown that an initial semi-quantitative score of 44 was
independently associated with failure to achieve complete remis-
sion after induction chemotherapy, although most other studies
showed only a trend or no significance to the initial mIBG score
(Perel et al, 1999; Matthay et al, 2003b; Katzenstein et al, 2004;
Yanik et al, 2010). Ongoing prospective studies of large numbers of
uniformly treated patients in North America and Europe will
further elucidate the prognostic significance of the initial mIBG
score.
Single-photon emission computed tomography views increase
the accuracy of geographical location of metastases, help
differentiate from physiological areas of uptake and increase the
sensitivity of detection on a lesion-by-lesion basis (Gelfand et al,
1994; Rufini et al, 1996). Single photon emission computed
tomography views are generally not used in calculating the mIBG
semi-quantitative score, because they are not routinely performed
at all institutions or on a uniform protocol. In non-paediatric
institutions, because of the longer time required for young
children with additional sedation, and increased expense, they
may not be regularly obtained. In the study by Vik et al (2009),
SPECT views only marginally increased the sensitivity from 88 to
91%. Although additional information was gained in 65% of cases
regarding the precise anatomic location of uptake, Curie scores
would not have been substantially altered. However, the addition
of SPECT views may be critical in cases in which there is a question
regarding physiological uptake vs tumour uptake, or for precise
localisation of a tumour focus that is critical for patient manage-
ment (e.g., distinguishing a vertebral lesion from the adjacent
pulmonary parenchyma). The addition of low-dose CT to SPECT
(SPECT/CT) for both lesion localisation and attenuation correction
has promise in providing more precise determination of the
anatomic location of disease (Tang et al, 2001; Rozovsky et al,
2008).
Other radiopharmaceuticals to assess disease
For those patients whose tumours are negative for mIBG uptake at
diagnosis, the 99mTechnetium MDP bone scan is the standard test
recommended to evaluate skeletal metastases (Gordon et al, 1990;
Brodeur et al, 1993; Perel et al, 1999). However, the low specificity
of this test and the difficulty interpreting uptake in young children
with actively growing bones make investigation of alternative
methods preferable. Several exploratory reports of the use of
18F-deoxyglucose positron emission tomography (FDG-PET) scans
suggest that this test also has a high specificity and sensitivity.
However, as FDG-PET measures a metabolic characteristic of the
tumour, while mIBG assesses the catecholamine reuptake pathway,
false positives may be observed in inflammatory lesions, and there
are also occasions when tumours may be FDG negative and mIBG
positive, or vice versa (Shulkin et al, 1996; Kushner et al, 2001;
Sharp et al, 2009). In newly diagnosed metastatic neuroblastoma,
and in relapsed neuroblastoma, in which the most common sites of
involvement are bone and bone marrow, recent studies suggest
higher sensitivity for mIBG than FDG-PET, because of greater
ability to detect the bone lesions, although the FDG-PET scans
are often more sensitive for small soft tissue tumours and nodal
metastases (Sharp et al, 2009; Taggart et al, 2009). Owing to the
physiological brain uptake of FDG, it may be less sensitive than
mIBG for lesions of the cranial vault (Kushner et al, 2001).
The clinical value of FDG-PET in neuroblastoma patients is at
present not well defined and the routine use of FDG-PET,
especially in case of intention to use this as a substitute for
123I-mIBG scintigraphy, is not justified. In mIBG-negative
tumours, the use of somatostatin receptor scintigraphy may be
considered in selected individual patients, although uptake of
111In-pentetreotide is more common in favourable prognosis
neuroblastoma (Schilling et al, 2000). Whole body MRI is also a
sensitive test for neuroblastoma tumours, including bone and bone
marrow metastases, although the specificity is much lower than
mIBG (Pfluger et al, 2003). Further prospective and comparative
studies will be needed to assess the relative merits of these
methods.
TIMING OF MIBG SCANS FOR RESPONSE
ASSESSMENT AND SURVEILLANCE
Metaiodobenzylguanidine scans should be performed in all high-risk
patients at diagnosis, before high-dose myeloablative therapy, and
before and after therapy given for minimal residual disease. Other
time points may be added according to assessments required to
evaluate the particular treatment regimen and as specified for
surveillance post-therapy. Metaiodobenzylguanidine scans have been
shown to be the most sensitive method for detecting both residual
bone disease and unsuspected asymptomatic relapse in high-risk
neuroblastoma (Kushner et al, 2009; Taggart et al, 2009). In a study of
113 patients with asymptomatic relapse, 123I-mIBG had 82%
sensitivity, compared with bone scan (36%) or bone marrow (34%)
for detection of tumour. In comparison with 18FDG-PET scan, mIBG
was significantly more sensitive for detection of bone lesions in
relapsed neuroblastoma, with 94% sensitivity compared with 43%
sensitivity in 122 individual bone lesions (Taggart et al, 2009).
Intermediate- and low-risk patients should have mIBG scans at
diagnosis, end of therapy and as surveillance at 6-month intervals
until 1 year for low-risk stage 2 and 2 years after therapy for
intermediate-risk patients. Although low- and intermediate-risk
neuroblastoma have an excellent overall survival 490%, the event-
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free survival is only approximately 80% for stage 2 (Perez et al, 2000),
stage 3 (Rubie et al, 1998), stage 4 and unfavourable biology 4 s
(Nickerson et al, 2000; Schmidt et al, 2000; Hero et al, 2008;
De Bernardi et al, 2009), suggesting that this modest surveillance
schedule is reasonable to detect relapsing patients.
SEMI-QUANTITATIVE MIBG SCORING
Historical development and assessment by the different
scoring systems
To evaluate the prognostic effect of tumour burden at diagnosis
and to be able to quantify response and define a partial response
(50% reduction of all disease sites) by mIBG scan, semi-
quantitative scoring systems have been developed (Ady et al,
1995; Suc et al, 1996; Perel et al, 1999; Frappaz et al, 2000; Matthay
et al, 2003b; Katzenstein et al, 2004; Messina et al, 2006; Lewington
et al, 2009). This improves the concordance between readers, and
enables one to differentiate a simple improvement with the
disappearance of a lesion, or decreased intensity of lesions that can
be subjective, from a significant response that would qualify as PR.
The scoring systems are all quite similar with minor variations,
and take into account the frequent diffuse nature of skeletal
involvement and the lack of precision if one attempted simply to
count individual lesions.
The most common scoring methods divide the skeleton into
anatomical sectors, then give each sector an individual score for
extension (quantity of metastases) and intensity (strength of
uptake). The sum of the scores for each sector gives a separate
mIBG score for extent and for intensity. Examples are shown in
Figures 1 and 2.
The first method reported was developed at the Curie Institute
in France (method 1; ‘Curie’) (Ady et al, 1995). It divides the
skeleton into nine segments to view osteomedullary involvement,
and adds a tenth sector that counts any soft tissue involvement
(Figure 1A). The extension score for method 1 is graded as: 0, no
sites per segment; 1, one site per segment; 2, more than one site per
segment; and 3, diffuse involvement (450% of the segment). The
intensity score is graded as: 0, for no uptake; 1, for doubtful
uptake; 2, for definite uptake less than liver; and 3, for intense
uptake greater than that of liver. Thus, the maximum score for
either extension or intensity would be 30. The Curie score (method
1) has been shown to have a good inter-observer concordance of
92 and 95% in two independent studies (Matthay et al, 2003b;
Messina et al, 2006). It has been validated in France and is now
widely used in North America for the New Approaches to
Neuroblastoma Therapy consortium and the Children’s Oncology
Group (COG). The Curie score has been shown in both retro-
spective and prospective analyses of scores at the end of induction
chemotherapy to correlate well with overall response and with
Figure 2 123I-mIBG scans and semi-quantitative scores on an 8 12 -year-old female with widespread skeletal involvement of stage 4 neuroblastoma.
Injection artefact from the portacath site in the left chest is observed in all images. The scores according to the three different methods most used are given;
the Curie score (method 1) is currently the standard of comparison for other scoring variations. (A) At diagnosis: method 1 (Curie)¼ 26 (by segment 3, 3,
3, 3, 3, 3, 1, 3, 3, 1); method 2 (Frappaz)¼ 21 (by segment: 3, 3, 3, 3, 3, 3, 3); method 3 (SIOPEN)¼ 61 (by segment: 5, 5, 5, 5, 4, 4, 6, 6, 6, 6, 4, 5).
(B) During induction: method 1¼ 1 for the soft tissue; method 2¼ 0; method 3¼ 0. (C) End therapy. Note the disappearance of soft tissue involvement
because of surgical resection of primary tumour: method 1¼ 0; method 2¼ 0; method 3¼ 0. (D) At relapse: method 1¼ 13 (by segment: 2, 1, 1, 1, 1, 1,
0, 3, 3, 0); method 2¼ 9 (by segment: 2, 0, 2, 1, 1, 2, 1); method 3¼ 29 (by segment: 3, 1, 1, 1, 0, 0, 1, 4, 5, 5, 4, 4).
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event-free survival (Matthay et al, 2003b; Messina et al, 2006;
Yanik et al, 2010). It was used as a reliable method for evaluating
response in patients with relapsed disease undergoing new
therapies (Matthay et al, 2006, 2009; Messina et al, 2006).
In 1996, Suc et al published a modification of the Curie score in
which the skeleton was divided into seven segments, and reported
that patients with a score 44 at diagnosis had a poorer outcome.
This system was subsequently shown to have good inter-observer
concordance, but did not show prognostic value for outcome on
further study (Frappaz et al, 2000). The Frappaz score (method 2)
uses seven segments of the skeleton, and initially did not include
soft tissue in the score, but noted it separately (Figure 1B). Thus,
for evaluation of skeletal disease, the methods were somewhat
comparable, but for assessing overall response by mIBG, method 2
was less accurate as initially reported, as soft tissue metastases
were not counted in the score, but noted separately (Messina et al,
2006). The score for method 2 was called an intensity score, and
graded for each segment as: 0, no uptake; 1, doubtful uptake; 2,
obvious but mild uptake; 3, strong uptake, with a maximum score
of 21. A separate qualitative ‘diffusion’ score was entered as 0 if
there was no uptake, 1 if uptake was spotty and 2 if uptake was
diffuse, with a maximum score of 14 (Frappaz et al, 2000).
Perel et al (1999) published another minor variation on the
Curie score, in which the skeleton was divided into 10 rather than 9
zones (the skull was divided into the calvarium and the base of the
skull, as in the Frappaz method), and soft tissue involvement was
ignored. Otherwise, this was identical to the Curie score. In a
subsequent publication, this method was shown to have prognostic
significance at the end of induction therapy, with a better outcome
for patients having a score of o3 (Katzenstein et al, 2004).
A third major variation was recently presented by Lewington
et al (2009) in a large group of neuroblastoma patients treated in
the high-risk neuroblastoma SIOPEN study (method 3; ‘SIOPEN’).
In the SIOPEN score, currently under prospective evaluation in
Europe, the skeletal distribution of mIBG was recorded in 12
anatomical body segments as follows: skull, thoracic cage,
proximal right upper limb, distal right upper limb, proximal left
upper limb, distal left upper limb, spine, pelvis, proximal right
lower limb, distal right lower limb, proximal left lower limb and
distal left lower limb (Figure 1C). The extent and pattern of skeletal
mIBG involvement was scored using a 0–6 scale to discriminate
between focal discrete lesions and patterns of more diffuse
infiltration. Each segment is scored as 0, no involvement; 1, one
discrete lesion; 2, two discrete lesions; 3, three discrete lesions; 4,
43 discrete foci or a single diffuse lesion involving o50% of a
bone; 5, diffuse involvement of450 to 95% whole bone; 6, diffuse
involvement of the entire bone, with a maximum score of 72. This
method showed 95% concordance in a blinded review by six
nuclear medicine physicians. It also proved slightly superior to the
Frappaz score as a measure of response evaluation (Lewington
et al, 2009).
Response evaluation by mIBG score
For response evaluation, the relative extension scores are
calculated by dividing the absolute post-therapy score by the
absolute pre-therapy score. A relative score of 0.5 is considered a
partial response; a relative score of 0 is a complete response
(Matthay et al, 2003b). Alternatively, an absolute score can be
shown to be a cut-off for a ‘good’ response (Ladenstein et al, 1998;
Katzenstein et al, 2004). A recent study of mIBG scores in the COG
study A3973 for 274 high-risk stage 4 neuroblastoma patients
showed a significantly worse EFS for patients with scores45 at the
end of induction (Yanik et al, 2010). It must be always considered
that any assessment of a prognostic factor is dependent on
uniform therapy and the particular therapy given; therefore,
results from one study may not be applicable to another with
different therapy.
In general, the sum for the intensity score and that for the
extension score correlate closely and do not change the conclusion
(Matthay et al, 2003b). However, as the intensity score is slightly
more subjective because of technical factors, showed lower
concordance among readers, and did not change the response
evaluation in two studies, it is not being used in recent and
ongoing prospective studies (Matthay et al, 2003b; Messina et al,
2006; Yanik et al, 2010).
The Curie score was more reliable than the Frappaz score for
evaluation of response in a blinded comparison, partly because of
the fact that the Frappaz score did not incorporate soft tissue
metastases into the score (Messina et al, 2006). The Curie
extension score is currently being used in large prospective phase
3 COG trials for high-risk neuroblastoma in North America
(A3973; ANBL0532) (Yanik et al, 2010). The SIOPEN score is the
current method being used in Europe for the prospective phase 3
neuroblastoma trial. Although both methods have shown good
inter-observer concordance and good correlation with outcome, at
the current time, the Curie score has been tested more widely and
over many years, and is less complex.
CONCLUSION
We suggest these guidelines for image acquisition and analysis to
facilitate high-quality studies in patients with neuroblastoma and
to achieve a high degree of consistency in interpretation. A semi-
quantitative method of image analysis is essential, and should
show low inter-observer variability and high reproducibility, while
providing a range of values for comparison with other indicators
of disease extent and response. We have adopted these guidelines
for application in upcoming cooperative neuroblastoma clinical
trials to validate them and test their utility in the management of
patients with neuroblastoma.
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